New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsComparePancragen vs LL-37

Pancragen vs LL-37

Side-by-side comparison of key properties, dosing, and research.

Anti-Aging & Longevity
Pancragen
Immune SupportRecovery & Repair
LL-37
Summary
Pancragen is a tripeptide bioregulator (Lys-Glu-Asp) developed by Professor Vladimir Khavinson, tissue-specific for the pancreas. It supports the function of both exocrine and endocrine pancreatic cells, promotes normalization of insulin secretion from beta cells, and may offer protective effects against pancreatic aging and diabetic progression.
LL-37 is the only known human cathelicidin antimicrobial peptide. It kills bacteria, fungi, and viruses by disrupting their membranes, while simultaneously modulating immune responses. Used for antimicrobial protection, immune priming, and wound healing.
Half-Life
Short (minutes); sustained gene-regulatory effects
Very short (~1–2 hours) in plasma due to protease degradation; topical use bypasses systemic clearance
Admin Route
SubQ, Oral
SubQ, Topical, Intranasal
Research
Typical Dose
10 mg per day
100–300 mcg
Frequency
Daily for 10–30 days
2–3x per week
Key Benefits
  • Supports pancreatic beta cell function and insulin secretion
  • May improve glucose metabolism in early metabolic dysfunction
  • Protective effects on exocrine pancreatic tissue
  • Anti-aging effects on pancreatic cells
  • Potential support in type 2 diabetes management alongside standard care
  • Reduces pancreatic cellular apoptosis from metabolic stress
  • Complementary to GLP-1 agonists in metabolic protocols
  • Broad-spectrum antimicrobial (bacteria, fungi, viruses)
  • Promotes wound healing and angiogenesis
  • Immune system modulation — enhances innate immunity
  • Reduces LPS-mediated endotoxemia
  • Anti-biofilm activity against resistant organisms
  • Promotes tissue regeneration and keratinocyte migration
  • May protect against sepsis
Side Effects
  • Generally well tolerated
  • Mild injection site reactions
  • No significant hypoglycemic events reported at standard doses as monotherapy
  • Injection site redness and irritation
  • Mild inflammatory response at injection site
  • Potential pro-inflammatory at high doses
  • Rare: fever or flu-like symptoms at initiation
Stacks With